Boehringer touts Pradaxa antidote data as FDA decision nears

Carly Helfand

LONDON– Ingelheim's currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker is hoping a nod for its candidate will help turn the tide in its favor.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS